Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial

RT @IDDocBerlin: @GermHunterMD Thanks. Looking forward for publication of SABATO results: https://t.co/IY0DcW9hGf

@GermHunterMD Thanks. Looking forward for publication of SABATO results: https://t.co/IY0DcW9hGf

https://t.co/K5S8G0Gw4p SABATO trial

Ongoing randomized trial to add to how we manage MRSA bacteremia, as recent evidence has shown oral therapy to be effective for other types of bacteremias and endocarditis. https://t.co/vocyCpvWBw and https://t.co/D9PT9wtTCt 2/2 https://t.co/rdZjqj1SMh

RT @JasonPBurnhamMD: So interesting. Only 23% said they would never give oral therapy for MSSA bacteremia. Maybe the other 77% know prelim…

So interesting. Only 23% said they would never give oral therapy for MSSA bacteremia. Maybe the other 77% know prelim results from https://t.co/qzB7MjFGav https://t.co/sw1DkaDVco

Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a… https://t.co/ifZElxTgEc

Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO)… https://t.co/zzM85Fnu0O

RT @IDPharmacist: Jordan Smith: oral therapy for S.aureus bacteremia? How about a clinical trial? https://t.co/eBXMzAD6zo #ncid15

Jordan Smith: oral therapy for S.aureus bacteremia? How about a clinical trial? https://t.co/eBXMzAD6zo #ncid15

RT @BRxAD: Study Protocol: Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO) https://t.co/d6i1a0U3…

Study Protocol: Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO) https://t.co/d6i1a0U3Is

RT @kadsho: Early oral switch therapy in low-risk Staphylococcus aureus BSI (SABATO): study protocol for a RCT #Trials http://t.co/M9CyV1l8…

RT @kadsho: Early oral switch therapy in low-risk Staphylococcus aureus BSI (SABATO): study protocol for a RCT #Trials http://t.co/M9CyV1l8…